Thus, in fast-growing malignancies such as osteosarcoma or pancreatic neuroendocrine tumors, ALT functions as a growth enabler whose benefits outweigh its costs, leading to poor prognosis [13,17]. This evidence concerns the gene GPT and pancreatic neuroendocrine tumor.